Showing results (1-10 of 7) with videos related to
Sort By:
Pageof 1
PDA Journal of Pharmaceutical Science and Technology|August 7, 2026
Pre-Announced vs. Unannounced FDA Drug Inspections: How Surprise Visits Change Enforcement Outcomes: Poster Presented at PDA Week 2026Michael de la Torre, Yelena Ionova, Barry PriceInternational Journal of Chronic Obstructive Pulmonary Disease|October 3, 2018
Effect of background long-acting beta2-agonist therapy on the efficacy and safety of a novel, nebulized glycopyrrolate in subjects with moderate-to-very-severe COPDEdward M Kerwin, Robert Tosiello, Barry Price, et al.Water Research|March 8, 2014
Applicability of passive compost bioreactors for treatment of extremely acidic and saline waters in semi-arid climatesVera Biermann, Adam M Lillicrap, Claudia Magana, et al.International Journal of Chronic Obstructive Pulmonary Disease|March 14, 2019
Efficacy and safety of glycopyrrolate in patients with COPD by reversibility: pooled analysis of GEM1 and GEM2 12-week studiesJill A Ohar, Alyssa Bowling, Thomas Goodin, et al.Respiratory Medicine|July 26, 2019
Effect of smoking status on lung function, patient-reported outcomes, and safety among patients with COPD treated with indacaterol/glycopyrrolate: Pooled analysis of the FLIGHT1 and FLIGHT2 studiesDonald P Tashkin, Thomas Goodin, Alyssa Bowling, et al.Respiratory Research|July 4, 2019
Effect of smoking status on lung function, patient-reported outcomes, and safety among COPD patients treated with glycopyrrolate inhalation powder: pooled analysis of GEM1 and GEM2 studiesDonald P Tashkin, Thomas Goodin, Alyssa Bowling, et al.COPD|June 28, 2019
Efficacy of Indacaterol/Glycopyrrolate in Patients with COPD by Airway Reversibility at Baseline: A Pooled Analysis of the FLIGHT1 and FLIGHT2 12-Week StudiesJill A Ohar, Sanjay Sharma, Thomas Goodin, et al.Pageof 1